EUROPEAN STUDY OF OLDER SUBJECTS WITH ATRIAL FIBRILLATION (EUROSAF)

• Research type

  Research Study

• Full title

  THE EUROPEAN STUDY OF OLDER SUBJECTS WITH ATRIAL FIBRILLATION (EUROSAF)

• IRAS ID

  213970

• Contact name

  Carlos Rodriguez-Pascual

• Contact email

  crodriguezpascual@lincoln.ac.uk

• Sponsor organisation

  United Lincolnshire NHS Trust

• Duration of Study in the UK

  1 years, 11 months, 31 days

• Research summary

  Atrial fibrillation (AF) is the most frequent cardiac arrhythmia that increases with age and is associated with higher risk of stroke, and mortality. Anticoagulant therapy is effective in preventing stroke and reducing mortality in these patients. The rate of anticoagulant prescribing in the older subjects with AF is less than 50%. The Multidimensional Prognostic Index (MPI) is a prognostic index for short- and long-term mortality.

  EUROSAF is a prospective observational study of 3.000 patients in 30 European Geriatric Medicine departments that will assess if: 1) a different risk of mortality, as assessed by the MPI, may influence the anticoagulant prescription; 2) the presence of multidimensional impairment, are usually not included in decision-making in older patients with AF; 3) the MPI information, can be useful identifying older patients with AF that can benefit from anticoagulant treatment in term of increased survival.

  Inclusion Criteria
  - Patients of both genders, aged 65 years and older
  - Admitted to hospital for acute diseases or a relapse of chronic diseases
  - With a documented diagnosis of non-valvular AF
  - Who are willing to participate in the survey and give their informed consent.

  Exclusion Criteria
  - Age less than 65 years
  - Patients who have not provided informed consent
  - Patients who lack capacity to consent

  Follow-up
  Six and twelve-month telephone contact.

• REC name

  Wales REC 7

• REC reference

  17/WA/0046

• Date of REC Opinion

  21 Mar 2017

• REC opinion

  Further Information Favourable Opinion